PORTRAZZA

PORTRAZZA is approved for use in combination with gemcitabine and cisplatin as the initial treatment for patients with metastatic squamous non-small cell lung cancer.

Portrazza (necitumumab) injection is used in combination with gemcitabine and cisplatin as a first-line treatment for patients with metastatic squamous non-small cell lung cancer. It works by blocking the epidermal growth factor receptor (EGFR).

PEMFEXY is recommended for use in combination with cisplatin as the first-line treatment for patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).

Infugem Gemcitabine injection is prescribed in combination with other medications, such as carboplatin, to effectively treat patients who have advanced ovarian cancer that has recurred at least 6 months after receiving previous treatment with platinum-based cancer drugs.

Vepesid® is prescribed for the treatment of Small Cell Carcinoma of the Lung, Malignant Lymphoma (histiocytic type), Non-small Cell Carcinoma of the Lung, and Testicular Malignancies.

CYTALUX is used in addition to other methods to help identify malignant lesions in adult patients with ovarian cancer during surgery.

Braftovi (encorafenib) in combination with Mektovi (binimetinib) has been approved by the FDA for the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients.

According to clinical trial results presented on Sunday, the pharmaceutical group AstraZeneca has developed a treatment called osimertinib, which is marketed under the name Tagrisso. This pill has been shown to reduce the risk of death from a specific type of lung cancer by 50% when taken daily after tumor removal surgery.

Dostarlimab, a type of immunotherapy, is a targeted treatment that aids the immune system in eliminating cancer. In the USA, a clinical trial is specifically studying rectal cancer patients with mutations in mismatch repair (MMR) genes, which are responsible for DNA repair.

Crizotinib (Xalkori) is a potential treatment for stage 4 non-small cell lung cancer that is ALK-positive. In cases where crizotinib cannot be taken, alternative drugs such as ceritinib (Zykadia), alectinib (Alecensaro), or brigatinib (Alunbrig) may be prescribed.

Osimertinib is administered orally on a daily basis and effectively eliminates lung cancer cells that possess these specific genetic mutations.

Pfizer (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for the use of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in the treatment of metastatic non-small cell lung cancer (NSCLC) in adult patients with a BRAF V600E mutation. This approval is contingent upon the use of an FDA-approved test to detect the mutation.

On November 15, 2023, the FDA granted approval to repotrectinib (Augtyro, Bristol-Myers Squibb Company) for the treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

In the United States, the overall 5-year relative survival rate for lung cancer is 23%. However, for non-small cell lung cancer (NSCLC), the 5-year relative survival rate is slightly higher at 28%.

According to state media reports on Monday, a new Chinese drug has demonstrated remarkable efficacy in treating a rare form of lung cancer, providing hope for patients battling the disease. The Phase 2 clinical trial of sunvozertinib, designed to target a specific type of lung cancer, has shown a 61% anti-tumor activity response.

In August 2023, the FDA granted Breakthrough Therapy Designation to Tagrisso in combination with chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic EGFRm NSCLC.

In the primary analysis group, Tagrisso treatment resulted in a five-year survival rate of 85%, while the placebo group had a rate of 73%. In the overall trial population, the five-year survival rate for Tagrisso was estimated to be 88%, compared to 78% for the placebo group.

No, Tagrisso is not classified as chemotherapy or immunotherapy. It is actually a targeted therapy specifically designed for treating certain types of non-small cell lung cancer. For more details regarding the uses of Tagrisso, please refer to the section titled “Tagrisso uses” below.

Tagrisso can be a viable alternative for individuals who have developed resistance to other oral EGFR inhibitors and have transitioned to chemotherapy. Another study demonstrated that Tagrisso extended the period without cancer progression by approximately 6 months in comparison to chemotherapy.

Studies have demonstrated that Tagrisso effectively reduces tumor size and slows down the progression of cancer in patients with these specific mutations.

DateArticleMar 31, 2017Approval Tagrisso (osimertinib) Receives Full Approval from the FDA
Nov 13, 2015Approval FDA Approves Tagrisso (osimertinib) for Non-Small Cell Lung Cancer with EGFR T790M Mutation

TAGRISSO offers the convenience of a once-daily dosing schedule.

Tagrisso (osimertinib), Retevmo (selpercatinib), and Rybrevant (amivantamab) are three medications used in the treatment of various types of cancer. Tagrisso is primarily used for non-small cell lung cancer, while Retevmo is used for both non-small cell lung cancer and thyroid cancer. Rybrevant is used for solid tumors, including non-small cell lung cancer.

For more information on these medications, you can refer to their respective prescribing information and related treatment guides.

Tagrisso, an EGFR inhibitor, is prescribed for the treatment of Non-Small Cell Lung Cancer. It is important to note that Tagrisso 80 mg is not classified as a controlled substance according to the Controlled Substances Act (CSA).

Osimertinib, a kinase inhibitor, is a medication used for the treatment of lung cancer. It effectively slows down or halts the growth of cancer cells by binding to a specific protein called epidermal growth factor receptor (EGFR) found in certain tumors.

Tagrisso is one of the brand names for Osimertinib.

Mechanism of Action: Portrazza (necitumumab) is a type of antibody called a recombinant human lgG1 monoclonal antibody. It works by attaching to a protein called the human epidermal growth factor receptor (EGFR) and preventing it from binding to other molecules in the body. This action helps to block the signaling pathway that is involved in the growth and spread of cancer cells.

Necitumumab, an anti-angiogenesis agent, is a human monoclonal antibody that targets the epidermal growth factor (EGF) receptor. It is utilized in the treatment of advanced non-small cell lung cancer.

Necitumumab, also known as INN, is a type of antineoplastic medication. It is a recombinant human IgG1 monoclonal antibody that is produced by the pharmaceutical company Eli Lilly.

Cetuximab, also known as Erbitux, is a targeted cancer drug used to treat advanced bowel cancer and head and neck cancers. It is often administered alongside other chemotherapy drugs or radiotherapy treatment, depending on the specific type of cancer.

Lurbinectedin (PM01183) is a compound derived from ecteinascidin, a substance found in marine sources. It works by attaching itself to the minor groove of DNA, causing breaks in the double-stranded DNA. Additionally, it hinders the activity of RNA-polymerase-II and facilitates its targeted breakdown through the ubiquitin/proteasome system.

30 Tagrisso 40 mg oral tablets will cost around $17,500, depending on the pharmacy you go to.